CHM chimeric therapeutics limited

Ann: ADVENT-AML Phase 1B clinical trial update, page-94

  1. 7,706 Posts.
    lightbulb Created with Sketch. 347
    You’ve made it clear you’re not questioning COH’s credibility — and that’s exactly why this situation warrants more balance.

    MD Anderson Cancer Center is leading the trial, and their involvement alone brings a level of clinical and ethical oversight that shouldn’t be dismissed lightly. They wouldn't risk their standing on flimsy data or allow their name to be associated with a company that’s misrepresenting trial outcomes.

    As for CHM — yes, healthy skepticism is fine, but the update was more than a “one-liner.” It outlined that two out of three patients achieved CRi, a meaningful and measurable clinical outcome, and that no safety issues have been observed so far. This is exactly the kind of early signal you’d expect in a Phase 1B study designed to evaluate whether CORE-NK cells can enhance the effectiveness of standard-of-care treatments like Azacitidine and Venetoclax.

    Suggesting alarm bells solely based on timing or forum chatter doesn’t acknowledge the complexity or credibility of a study being run by one of the top cancer centres in the world.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $9.747M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $1.858K 619.3K

Buyers (Bids)

No. Vol. Price($)
66 58647032 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 107164382 32
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.